PARLIAMENTARY WRITTEN QUESTION
(9 February 2026)

To ask the Secretary of State for Environment, Food and Rural Affairs, whether she has assessed the potential merits of amending the user risk mitigation advice for spot-on pet treatments to include all sources of the potential impact of short and long term exposure in households where pets are treated routinely, including on children.

Asked by:
Jayne Kirkham (Labour)

Veterinary Medicinal Products (VMPs) undergo a product-specific user risk assessment that considers all those that may come into contact with the medicine, including adults and children. This assessment considers the identified hazards of the medicine, the likely exposure to adults and children when VMPs are used as recommended and concludes on the likely risks to humans. The identified risks are mitigated using appropriate packaging and user safety warnings on the product information supplied with the medicines. Once authorised for marketing, pharmacovigilance reporting provides further data from use of these medicines in real-world situations, and these data are used to consider any changes required to reduce identified risks, such as updating the user safety warnings. If a concern with the current mitigations is identified, then the advice can be updated.

Answered by:
()